SMEs are "a motor of innovation," says EMA


Pharma Times

Published 02 February 2014

Over 40% of innovative medicines recommended for marketing authorisation (MA) in the European Union (EU) during 2010-12 originated from small or medium-sized enterprises (SMEs), academia, public bodies and public-private partnerships, according to new research.

The full article is available here.